Principal Financial Group Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) ...

Brian Skorney has given his Buy rating due to a combination of factors including the recent failure of AbbVie’s emraclidine in Phase 2 trials, which opens up an opportunity for Neurocrine Biosciences ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Jefferies analyst Akash Tewari maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $158.00.

Discover TD” gamified patient scenarios to help health care professionals accurately diagnose tardive dyskinesia.

Q3 2024 Earnings Call Transcript October 30, 2024 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective cut by BMO Capital Markets from $128.00 to $114.00 in a research note published on Thursday, Benzinga reports.

The biotech company reported strong growth in both revenue and earnings, driven largely by the sales of its flagship drug, Ingrezza.

US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...